Evidence Level:Sensitive: C3 – Early Trials
Title:
First-in-human, multicenter phase Ⅰ study of TGRX-326 in patients with advanced ALK-positive non-small cell lung cancer.
Excerpt:TGRX-326 demonstrated antitumor activity against multiple ALK mutations including G1202R.
DOI:10.1200/JCO.2023.41.16_suppl.9113